119 related articles for article (PubMed ID: 30065912)
1. Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma.
Xu L; Xia C; Sun Q; Sheng F; Xiong J; Wang S
J Bone Oncol; 2018 Sep; 12():44-48. PubMed ID: 30065912
[TBL] [Abstract][Full Text] [Related]
2. A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment.
Hagleitner MM; Coenen MJ; Gelderblom H; Makkinje RR; Vos HI; de Bont ES; van der Graaf WT; Schreuder HW; Flucke U; van Leeuwen FN; Hoogerbrugge PM; Guchelaar HJ; te Loo DM
Clin Cancer Res; 2015 Aug; 21(15):3436-41. PubMed ID: 25829401
[TBL] [Abstract][Full Text] [Related]
3. FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.
El-Hamamsy M; Ghali RR; Saad AS; Shaheen SM; Salem AM
Onco Targets Ther; 2016; 9():6857-6863. PubMed ID: 27853379
[TBL] [Abstract][Full Text] [Related]
4. Distinct role of the Fas rs1800682 and FasL rs763110 polymorphisms in determining the risk of breast cancer among Han Chinese females.
Wang M; Wang Z; Wang XJ; Jin TB; Dai ZM; Kang HF; Guan HT; Ma XB; Liu XH; Dai ZJ
Drug Des Devel Ther; 2016; 10():2359-67. PubMed ID: 27524883
[TBL] [Abstract][Full Text] [Related]
5. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S
Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541
[TBL] [Abstract][Full Text] [Related]
6. A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of C/EBPβ and OCT1 complex to chromatin.
Wu S; Wang S; Fu Y; Tang W; Jin H; Meng Q; Zhang C; Cui M; Cao X; Li X; Zhang Z; Chen R
Int J Cancer; 2017 Feb; 140(4):756-763. PubMed ID: 27790710
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms rs763110 in
Huang P; Wang CH; Zhuo LY; Xia XS; Yang S; Zhang JW; Fan HZ; Wu JJ; Yu R; Yue M; Zhang Y
Br J Biomed Sci; 2020 Jul; 77(3):112-117. PubMed ID: 32209020
[TBL] [Abstract][Full Text] [Related]
8. Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Renner W; Gerger A; Kapp KS; Langsenlehner T
Strahlenther Onkol; 2014 Mar; 190(3):304-9. PubMed ID: 24424626
[TBL] [Abstract][Full Text] [Related]
9. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis.
Yıldır S; Sezgin M; Barlas IÖ; Türköz G; Ankaralı HÇ; Şahin G; Erdal ME
Rheumatol Int; 2013 Oct; 33(10):2637-45. PubMed ID: 23749041
[TBL] [Abstract][Full Text] [Related]
10. Associations between FAS rs2234767 and FASL rs763110 polymorphisms and the risk of lung cancer: a meta-analysis of 39,736 subjects.
Yu X; Li Y; Yu Y; Lei J; Wan G; Cao F
Onco Targets Ther; 2016; 9():2049-56. PubMed ID: 27103831
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review.
Hurkmans EGE; Brand ACAM; Verdonschot JAJ; Te Loo DMWM; Coenen MJH
BMC Cancer; 2022 Dec; 22(1):1326. PubMed ID: 36536332
[TBL] [Abstract][Full Text] [Related]
12. Single-Nucleotide Polymorphisms of FAS and FASL Genes and Risk of Idiopathic Aplastic Anemia.
Rehman S; Saba N; Naz M; Ahmed P; Munir S; Sajjad S; Tabassum S; Naseem L
Immunol Invest; 2018 Jul; 47(5):484-491. PubMed ID: 29611722
[TBL] [Abstract][Full Text] [Related]
13. Effect of ABCB1 polymorphism on the clinical outcome of osteosarcoma patients after receiving chemotherapy.
Xiaohui S; Aiguo L; Xiaolin G; Ying L; Hongxing Z; Yilei Z
Pak J Med Sci; 2014 Jul; 30(4):886-90. PubMed ID: 25097538
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
15. Functional variant of IL33 is associated with survival of osteosarcoma patients.
Lin Q; Han J; Sun Q; Wen L; Wang S
J Bone Oncol; 2020 Feb; 20():100270. PubMed ID: 31890491
[TBL] [Abstract][Full Text] [Related]
16. FasL (rs763110) gene polymorphism is not associated with susceptibility to rheumatoid arthritis in Croatian population.
Artuković M; Ikić Matijašević M; Markotić A; Šućur A; Grčević D; Kovačić N; Flegar D; Stipić Marković A; Šisl D; Artuković I; Kelava T
Croat Med J; 2020 Dec; 61(6):547-555. PubMed ID: 33410302
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
18. The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.
Zhang Z; Qiu L; Wang M; Tong N; Li J; Zhang Z
Eur J Hum Genet; 2009 Oct; 17(10):1294-303. PubMed ID: 19337311
[TBL] [Abstract][Full Text] [Related]
19. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
20. FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.
Xu L; Zhou X; Jiang F; Qiu MT; Zhang Z; Yin R; Xu L
PLoS One; 2013; 8(9):e74543. PubMed ID: 24086353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
